Galderma Korea said Friday that it will launch “Restylane Eyelight,” a new product of its premium hyaluronic acid filler brand Restylane, in June in Korea.Restylane Eyelight features Galderma's proprietary “NASHA” technology, a patented process that enables precise treatment of difficult facial area
HLB bioStep, a Korean non-clinical CRO, said Friday that it has acquired Croen, a company specializing in GLP (Good Laboratory Practice) toxicity testing.Through this acquisition, HLB bioStep will provide integrated nonclinical services for drug development by securing the capability to conduct vari
OliX Pharmaceuticals’ short interfering ribonucleic acid (siRNA)-based hypertrophic scar treatment OLX10010 (OLX101A) has raised questions in the market due to the omission of certain information, including safety assessments, in the published results of its phase 2a clinical trial.On Wednesday, Oli
The clinical significance of the new antibody-drug conjugate (ADC) drug Enhertu (trastuzumab deruxtecan), which was launched by AstraZeneca and Daiichi Sankyo and won health insurance coverage in Korea this month, gained attention among breast cancer specialists at a recent conference in Seoul.A sym
Biotech startups supported by Celltrion through its “open innovation strategy” are nesting in Seoul Biohub.Celltrion said Thursday that it attended the Seoul Biohub Global Center opening ceremony in Dongdaemun-gu, Seoul. Three companies supported by Celltrion—MediMabBio, S&K Therapeutics, and Entero
Novartis' angiotensin receptor-neprilysin inhibitor (ARNI) heart failure treatment Entresto (sacubitril/valsartan) has reduced hospitalization rates in patients with newly diagnosed (de novo) heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fract
AI solutions developed by Korean medical artificial intelligence companies, including Lunit, have begun to be used in medical sites, raising expectations among market players and the medical community.On Tuesday last week, Lunit, Coreline Soft, and Deepnoid received the results of the National Evide
Skyrizi (risankizumab) has emerged as a new option for treating palmoplantar pustulosis (PPP), a condition characterized by pustules, exfoliation, and red patches on the palms of the hands and feet that impair quality of life.AbbVie Korea held a media event on Monday to commemorate the approval of i
Atrial fibrillation (AF) is one of the most common arrhythmias, with a higher prevalence in older adults. It significantly increases the risk of stroke, and the number of patients is increasing with the aging population in many countries, including Korea. Currently, the main anticoagulants used to t
Professor Jung Mi-hyang of the Department of Cardiology at the Catholic University of Korea St. Mary's Hospital was recently appointed associate editor of the European Journal of Preventive Cardiology.The European Journal of Preventive Cardiology (IF:8.526), the official journal of the European Soci
SK biopharmaceuticals said Thursday it has signed a technology transfer agreement with a Chinese joint venture company, Ignis Therapeutics, for a non-narcotic pain treatment candidate worth 80.4 billion won ($58 million).Under the agreement, SK biopharmaceuticals will transfer the global development
A clinical study has shown that Orafang tablets are safe for people in their 40s and 50s and for the very elderly aged 70 or more.Pharmbio Korea said Tuesday that it presented clinical results at the Seventh International Meeting on Intestinal Diseases, which was held in conjunction with the Annual
AstraZeneca Korea's Tagrisso (osimertinib) has expanded its indication to include the first-line treatment of EGFR-mutated non-squamous NSCLC.The Ministry of Food and Drug Safety on Monday approved Tagrisso in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment o
Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin's lymphoma, which accounts for the majority of lymphomas. In addition, the number of B-cell lymphoma patients in Korea is increasing due to the westernization of lifestyle and population aging.DLBCL is characterized by
Lunit, a Korean medical AI company, has moved closer to acquiring Volpara Health Technologies, a New Zealand company specializing in AI-powered cancer examining software.Volpara said its shareholders approved the deal with 96.92 percent of the votes cast at the company's annual general meeting last
PharmaEssentia Korea said it hosted a myeloproliferative neoplasms (MPN) forum to share the latest insights on Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV) on Thursday last week.The forum featured two world-renowned experts in the field of MPN -- Professor Hans Carl Hass
KBIOHealth (Osong Medical Innovation Foundation) has set up an office in Japan, raising expectations of cooperation between the two countries’ biotech industries.KBIOHealth said it opened an office (KBIOHealth JAPAN Office) in Shonan iPark, located in Kanagawa Prefecture, and held a signboard-hangin
GI Innovation is accelerating the development of a subcutaneous (SC) formulation of its immuno-oncology candidate GI-102.The company said Tuesday that it has applied for approval to change the IND (investigational new drug) application for the GI-102 phase 1/2a clinical trial to the Ministry of Food
Celltrion said it has completed a registration contract for its subcutaneous (SC) Remicade biosimilar, Zymfentra (infliximab), with one of the top three pharmaceutical benefit managers (PBMs) in the United States."We are pleased to announce through our website that we have successfully closed a deal
Amid a growing consensus that domestic and international medical practitioners should collaborate to find solutions to the growing risk of pancreatic and biliary tract diseases, some experts stressed the need for active state support for research investment to develop treatments and diagnostics.The